R. Sutherland

Oncology · Nature · 2009–2016

A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom R. Sutherland trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. G. Shapiro (in Oncology)

Papers from R. Sutherland's perspective

Ordered by how strongly the researchers R. Sutherland trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  2. Concordance among gene-expression-based predictors for breast cancer. (New England Journal of Medicine)
  3. Breast cancer classification and prognosis based on gene expression profiles from a population-based study (Proceedings of the National Academy of Sciences of the United States of America)
  4. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. (Journal of the National Cancer Institute)
  5. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. (Journal of the National Cancer Institute)
  6. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. (Journal of Clinical Oncology)
  7. Whole genomes redefine the mutational landscape of pancreatic cancer (Nature)
  8. The hallmarks of cancer (RNA Biology)
  9. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)
  10. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. (New England Journal of Medicine)

Their papers